A Randomized-Controlled Trial to Examine the Effects of a Daily Probiotic Supplement on Common Symptoms of Menopause

Symptoms of menopause can significantly affect overall quality of life. It is hypothesized that probiotic supplements can reduce the severity of these symptoms. This 90-day randomized controlled trial will examine the effects of the Provitalize Natural Menopause Probiotic on weight loss, waist circumference, sleep, and symptoms of menopause including hot flashes, night sweats, mood swings, anxiety, fatigue and brain fog. Participants will take either the test product or a placebo daily. All participants will complete study-specific questionnaires and provide sleep data from their Fitbit at Baseline, Day 30, Day 60 and Day 90. At Baseline, Day 30, Day 60 and and Day 90, participants will also provide a bodyweight measurement and a waist circumference measurement.

Study Overview

• Status: Completed
• Conditions: Menopause
• Intervention / Treatment: Dietary supplement: Provitalize Natural Menopause Probiotic; Other: Placebo

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Santa Monica, California, United States, 90404
      • Citruslabs

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Women aged 45-65 years old
• Must experience hot flashes and/or night sweats at least once per day
• Must also be experiencing at least two symptoms of menopause, such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, weight gain, or vaginal changes
• Can be either natural or surgical menopause
• Has not had a period in the last 12 consecutive months
• Willing to adhere to the study protocol for the duration of the study
• Willing to stop taking any other herbal remedies or supplements for the duration of the study
• Self-reports as "generally healthy"
• Has never taken Provitalize before
• No planned invasive medical procedures for the duration of the study or in the three weeks leading up to the study start

Exclusion Criteria:

• Not experiencing hot flashes and/or night sweats at least once per day and two other symptoms of menopause such as sleep disturbances, mood changes, fatigue and lack of energy, changes in sexual function, urinary changes, irregular or absent periods, or vaginal changes
• Unwilling to stop taking any other herbal remedies or supplements for the duration of the study
• Current use of conventional hormone replacement therapies, or plan to start during the study duration
• Current use of hormonal birth control, or plan to start during the study duration
• Known allergies or hypersensitivities to any product ingredients
• Current or history of uterine fibroids, endometriosis, polycystic ovarian syndrome, or history of abnormal pap smear
• Anyone with any known severe allergies requiring the use of an epi-pen
• Unwilling to adhere to the study protocol
• Anyone living with uncontrolled or chronic health disorders, including oncological or psychiatric disorders
• Pregnant, breastfeeding or trying to conceive
• Currently taking a prescription sleep aid

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Provitalize Probiotic; Participants will take 2 capsules every morning on an empty stomach before their first meal of the day.	Dietary supplement: Provitalize Natural Menopause Probiotic; Supplement containing a Probiotic blend of Bifidobacterium breve, Lactobacillus Gasseri, and Bifidobacterium animalis subsp. Lactis.
Placebo Comparator: Placebo; Participants will take 2 capsules every morning on an empty stomach before their first meal of the day.	Other: Placebo; Placebo comparator containing Pure hydroxypropyl methylcellulose (HPmC) with food dye.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in body weight. [Timeframe: Baseline to Day 90]	Participants will weigh themselves using a Fitbit Smart Scale that they will be provided with.	90 days
Change in waist circumference. [Timeframe: Baseline to Day 90]	Participants will measure their waist circumference using a tape measure that they will be provided with.	90 days
Changes in scores on the Bristol Stool Chart. [Timeframe: Baseline to Day 90]	The Bristol Stool Chart is widely used as a research tool to evaluate the effectiveness of treatments for various diseases of the bowel. Types 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, 5 indicating lack of dietary fiber, and 6 and 7 indicate diarrhoea.	90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in the frequency of hot flashes. [Timeframe: Baseline to Day 90]	Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.	90 days
Changes in the frequency of night sweats. [Timeframe: Baseline to Day 90]	Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.	90 days
Changes in the severity of brain fog experienced. [Timeframe: Baseline to Day 90]	Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.	90 days
Changes in the severity of mood swings. [Timeframe: Baseline to Day 90]	Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.	90 days
Changes in the severity of fatigue. [Timeframe: Baseline to Day 90]	Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.	90 days
Changes in the severity of bloating. [Timeframe: Baseline to Day 90]	Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.	90 days
Changes in the frequency of bloating. [Timeframe: Baseline to Day 90]	Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.	90 days
Changes in the severity of joint pain. [Timeframe: Baseline to Day 90]	Measured via study-specific questionnaires using a 5-point Likert scale. A lower score indicates a more favourable response, with 0=Not noticeable and 4=Severe.	90 days
Changes in total time asleep. [Timeframe: Baseline to Day 90]	Measured using Fitbit wearable sleep tracker.	90 days
Changes in overall sleep score provided by Fitbit wearable sleep tracker. [Timeframe: Baseline to Day 90]	The sleep score is based on heart rate, the time spent awake or restless, and sleep stages. The score is given out of 100, with 100 indicating the best possible score.	90 days
Changes in total time awake at night. [Timeframe: Baseline to Day 90]	Measured using Fitbit wearable sleep tracker.	90 days

Collaborators and Investigators

• Sponsor: Maneuver Marketing
• Collaborators: Citruslabs

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2023
• Primary Completion (Actual): June 15, 2024
• Study Completion (Actual): June 15, 2024

Study Registration Dates

• First Submitted: November 19, 2023
• First Submitted That Met QC Criteria: November 19, 2023
• First Posted (Actual): November 28, 2023

Study Record Updates

• Last Update Posted (Estimated): November 20, 2024
• Last Update Submitted That Met QC Criteria: November 18, 2024
• Last Verified: November 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: 20379

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No